Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study

被引:28
作者
Yang, Jeong Hoon [1 ,2 ]
Hahn, Joo-Yong [1 ]
Bin Song, Young [1 ]
Choi, Seung-Hyuk [1 ]
Choi, Jin-Ho [1 ]
Lee, Sang Hoon [1 ]
Jeong, Myung-Ho [3 ]
Choi, Dong-Joo [4 ]
Park, Jong Seon [5 ]
Park, Hun Sik [6 ]
Gwon, Hyeon-Cheol [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Cardiol,Dept Med, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Crit Care Med, Seoul, South Korea
[3] Chonnam Natl Univ Hosp, Dept Med, Div Cardiol, Kwangju, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Dept Med, Div Cardiol, Songnam, South Korea
[5] Yeungnam Univ Hosp, Dept Med, Taegu, South Korea
[6] Kyungpook Natl Univ Hosp, Dept Med, Taegu, South Korea
来源
BMJ-BRITISH MEDICAL JOURNAL | 2014年 / 349卷
关键词
CONVERTING ENZYME-INHIBITORS; HIGH-RISK; TELMISARTAN; CAPTOPRIL; METAANALYSIS; DYSFUNCTION; MORTALITY; TRIAL;
D O I
10.1136/bmj.g6650
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate the association between treatment with an angiotensin receptor blocker and clinical outcomes in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function. Design A prospective cohort study using data from a nationwide large scale registry. Setting 53 hospitals involved in treatment of acute myocardial infarction in Korea. Participants Between November 2005 and September 2010, we studied 6698 patients with ST segment elevation myocardial infarction who underwent primary percutaneous coronary intervention and had a left ventricular ejection fraction >= 40%. Main outcome measures Cardiac death or myocardial infarction. Patients were divided into an angiotensin receptor blocker group (n=1185), an angiotensin converting enzyme (ACE) inhibitor group (n=4564), and a group who did not receive any renin angiotensin system blocker (n=949). Propensity score matching analysis was also performed. Results Cardiac death or myocardial infarction occurred in 21 patients (1.8%) in the angiotensin receptor blocker group, 77 patients (1.7%) in the ACE inhibitor group, and 33 patients (3.5%) in the no renin angiotensin system blocker group. After propensity score matching (1175 pairs), there was no significant difference in the rate of cardiac death or myocardial infarction between the angiotensin receptor blocker group and ACE inhibitor group (21 (1.8%) v 23 (2.0%), adjusted hazard ratio 0.65, 95% confidence interval 0.30 to 1.38; P=0.65). The angiotensin receptor blocker group had a lower rate of cardiac death or myocardial infarction than the no renin angiotensin system blocker group in matched populations (803 pairs) (14 (1.7%) v 25 (3.1%), 0.35, 0.14 to 0.90; P=0.03). Conclusion Angiotensin receptor blocker showed beneficial effects comparable with ACE inhibitors in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function. Angiotensin receptor blockers could be used as an alternative to ACE inhibitors in such patients.
引用
收藏
页数:12
相关论文
共 18 条
[11]   EFFECT OF CAPTOPRIL ON MORTALITY AND MORBIDITY IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION - RESULTS OF THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL [J].
PFEFFER, MA ;
BRAUNWALD, E ;
MOYE, LA ;
BASTA, L ;
BROWN, EJ ;
CUDDY, TE ;
DAVIS, BR ;
GELTMAN, EM ;
GOLDMAN, S ;
FLAKER, GC ;
KLEIN, M ;
LAMAS, GA ;
PACKER, M ;
ROULEAU, J ;
ROULEAU, JL ;
RUTHERFORD, J ;
WERTHEIMER, JH ;
HAWKINS, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (10) :669-677
[12]   Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [J].
Pfeffer, MA ;
McMurray, JJV ;
Velazquez, EJ ;
Rouleau, JL ;
Kober, L ;
Maggioni, AP ;
Solomon, SD ;
Swedberg, K ;
Van de Werf, F ;
White, H ;
Leimberger, JD ;
Henis, M ;
Edwards, S ;
Zelenkofske, S ;
Sellers, MA ;
Califf, RM ;
Aylward, P ;
Armstrong, P ;
Barvik, S ;
Belenkov, Y ;
Dalby, A ;
Diaz, R ;
Drexler, H ;
Ertl, G ;
Francis, G ;
Hampton, J ;
Harsanyi, A ;
Kvasnicka, J ;
Mareev, V ;
Marin-Neto, J ;
Murin, J ;
Myers, M ;
Nordlander, R ;
Opolski, G ;
Soler-Soler, J ;
Spac, J ;
Stefenelli, T ;
Sugrue, D ;
Van Gilst, W ;
Varshavsky, S ;
Weaver, D ;
Zannad, F ;
Aguilar, D ;
Alvarez, A ;
Al-Taweel, M ;
Anavekar, N ;
Finn, P ;
Lopez-Jimenez, F ;
Mercier, R ;
Lewis, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (20) :1893-1906
[13]   Combining propensity score matching with additional adjustments for prognostic covariates [J].
Rubin, DB ;
Thomas, N .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2000, 95 (450) :573-585
[14]   A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure [J].
Savarese, Gianluigi ;
Costanzo, Pierluigi ;
Cleland, John George Franklin ;
Vassallo, Enrico ;
Ruggiero, Donatella ;
Rosano, Giuseppe ;
Perrone-Filardi, Pasquale .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (02) :131-142
[15]   ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation [J].
Steg, Ph. Gabriel ;
James, Stefan K. ;
Atar, Dan ;
Badano, Luigi P. ;
Blomstrom-Lundqvist, Carina ;
Borger, Michael A. ;
Di Mario, Carlo ;
Dickstein, Kenneth ;
Ducrocq, Gregory ;
Fernandez-Aviles, Francisco ;
Gershlick, Anthony H. ;
Giannuzzi, Pantaleo ;
Halvorsen, Sigrun ;
Huber, Kurt ;
Juni, Peter ;
Kastrati, Adnan ;
Knuuti, Juhani ;
Lenzen, Mattie J. ;
Mahaffey, Kenneth W. ;
Valgimigli, Marco ;
van't Hof, Arnoud ;
Widimsky, Petr ;
Zahger, Doron .
EUROPEAN HEART JOURNAL, 2012, 33 (20) :2569-2619
[16]   Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial [J].
Yusuf, S. ;
Teo, K. ;
Anderson, C. ;
Pogue, J. ;
Dyal, L. ;
Copland, I. ;
Schumacher, H. ;
Dagenais, G. ;
Sleight, P. .
LANCET, 2008, 372 (9644) :1174-1183
[17]   Telmisartan to prevent recurrent stroke and cardiovascular events [J].
Yusuf, Salim ;
Diener, Hans-Christoph ;
Sacco, Ralph L. ;
Cotton, Daniel ;
Ounpuu, Stephanie ;
Lawton, William A. ;
Palesch, Yuko ;
Martin, Renee H. ;
Albers, Gregory W. ;
Bath, Philip ;
Bornstein, Natan ;
Chan, Bernard P. L. ;
Chen, Sien-Tsong ;
Cunha, Luis ;
Dahlof, Bjorn ;
De Keyser, Jacques ;
Donnan, Geoffrey A. ;
Estol, Conrado ;
Gorelick, Philip ;
Gu, Vivian ;
Hermansson, Karin ;
Hilbrich, Lutz ;
Kaste, Markku ;
Lu, Chuanzhen ;
Machnig, Thomas ;
Pais, Prem ;
Roberts, Robin ;
Skvortsova, Veronika ;
Teal, Philip ;
Toni, Danilo ;
VanderMaelen, Cam ;
Voigt, Thor ;
Weber, Michael ;
Yoon, Byung-Woo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (12) :1225-1237
[18]   Telmisartan, ramipril, or both in patients at high risk for vascular events [J].
Yusuf, Salim ;
Teo, Koon K. ;
Pogue, Janice ;
Dyal, Leanne ;
Copland, Ingrid ;
Schumacher, Helmut ;
Ingelheim, Boehringer ;
Dagenais, Gilles ;
Sleight, Peter ;
Anderson, Craig .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (15) :1547-1559